These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1037 related articles for article (PubMed ID: 19451443)

  • 1. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
    De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
    J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer.
    Du Y; Cullum I; Illidge TM; Ell PJ
    J Clin Oncol; 2007 Aug; 25(23):3440-7. PubMed ID: 17592153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus.
    Guo H; Zhu H; Xi Y; Zhang B; Li L; Huang Y; Zhang J; Fu Z; Yang G; Yuan S; Yu J
    J Nucl Med; 2007 Aug; 48(8):1251-8. PubMed ID: 17631554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation among [18F]fluorodeoxyglucose positron emission tomography/computed tomography, cancer antigen 27.29, and circulating tumor cell testing in metastatic breast cancer.
    Saad A; Kanate A; Sehbai A; Marano G; Hobbs G; Abraham J
    Clin Breast Cancer; 2008 Aug; 8(4):357-61. PubMed ID: 18757264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of hematogenous bone metastasis in cervical cancer: 18F-fluorodeoxyglucose-positron emission tomography versus computed tomography and magnetic resonance imaging.
    Liu FY; Yen TC; Chen MY; Lai CH; Chang TC; Chou HH; Hong JH; Chen YR; Ng KK
    Cancer; 2009 Dec; 115(23):5470-80. PubMed ID: 19739235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
    Krause BJ; Herrmann K; Wieder H; zum B├╝schenfelde CM
    J Nucl Med; 2009 May; 50 Suppl 1():89S-96S. PubMed ID: 19380406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
    Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
    J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?
    Dawood S; Broglio K; Valero V; Reuben J; Handy B; Islam R; Jackson S; Hortobagyi GN; Fritsche H; Cristofanilli M
    Cancer; 2008 Nov; 113(9):2422-30. PubMed ID: 18785255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.
    Park JW; Kim JH; Kim SK; Kang KW; Park KW; Choi JI; Lee WJ; Kim CM; Nam BH
    J Nucl Med; 2008 Dec; 49(12):1912-21. PubMed ID: 18997056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
    Wu ZJ; Zhang YX; Wei H; Jia Q
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG PET-CT in the management of primary breast lymphoma.
    Santra A; Kumar R; Reddy R; Halanaik D; Kumar R; Bal CS; Malhotra A
    Clin Nucl Med; 2009 Dec; 34(12):848-53. PubMed ID: 20139815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer ?].
    Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Yoneda M; Abe Y; Inamori M; Kirikoshi H; Kubota K; Saito S; Nakajima A
    Gan To Kagaku Ryoho; 2008 Jan; 35(1):65-70. PubMed ID: 18195530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
    Cohen SJ; Punt CJ; Iannotti N; Saidman BH; Sabbath KD; Gabrail NY; Picus J; Morse M; Mitchell E; Miller MC; Doyle GV; Tissing H; Terstappen LW; Meropol NJ
    J Clin Oncol; 2008 Jul; 26(19):3213-21. PubMed ID: 18591556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries.
    Schwarz JK; Grigsby PW; Dehdashti F; Delbeke D
    J Nucl Med; 2009 May; 50 Suppl 1():64S-73S. PubMed ID: 19380409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.
    Cristofanilli M; Hayes DF; Budd GT; Ellis MJ; Stopeck A; Reuben JM; Doyle GV; Matera J; Allard WJ; Miller MC; Fritsche HA; Hortobagyi GN; Terstappen LW
    J Clin Oncol; 2005 Mar; 23(7):1420-30. PubMed ID: 15735118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival.
    Hayes DF; Cristofanilli M; Budd GT; Ellis MJ; Stopeck A; Miller MC; Matera J; Allard WJ; Doyle GV; Terstappen LW
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4218-24. PubMed ID: 16857794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer.
    De Giorgi U; Mego M; Rohren EM; Liu P; Handy BC; Reuben JM; Macapinlac HA; Hortobagyi GN; Cristofanilli M; Ueno NT
    J Nucl Med; 2010 Aug; 51(8):1213-8. PubMed ID: 20660382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.
    Goerres GW; Stupp R; Barghouth G; Hany TF; Pestalozzi B; Dizendorf E; Schnyder P; Luthi F; von Schulthess GK; Leyvraz S
    Eur J Nucl Med Mol Imaging; 2005 Feb; 32(2):153-62. PubMed ID: 15690223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome.
    Karam M; Ata A; Irish K; Feustel PJ; Mottaghy FM; Stroobants SG; Verhoef GE; Chundru S; Douglas-Nikitin V; Oliver Wong CY; Brepoels LM
    Nucl Med Commun; 2009 Oct; 30(10):770-8. PubMed ID: 19657307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.
    Ceresoli GL; Chiti A; Zucali PA; Rodari M; Lutman RF; Salamina S; Incarbone M; Alloisio M; Santoro A
    J Clin Oncol; 2006 Oct; 24(28):4587-93. PubMed ID: 17008700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.